TerrAscend (TSNDF) Income from Non-Controlling Interests (2021 - 2026)

TerrAscend's (TSNDF) quarterly Income from Non-Controlling Interests came in at $1.1 million in Q1 2026, down 18.89% year-on-year from $1.3 million in Q1 2025, and down 5.04% on a QoQ basis from $1.1 million in Q4 2025.

TerrAscend (TSNDF) Income from Non-Controlling Interests (2021 - 2026) Analysis & Trends

TerrAscend (TSNDF) has 6 years of Income from Non-Controlling Interests data on file, last reported at $1.1 million in Q1 2026.

  • On a quarterly basis, Income from Non-Controlling Interests fell 18.89% year-over-year to $1.1 million in Q1 2026; TTM through Mar 2026 was $4.7 million, a 30.17% decrease from a year earlier, with the FY2025 full-year figure at $4.9 million, down 35.24% from the prior year.
  • Income from Non-Controlling Interests for Q1 2026 stood at $1.1 million, down from $1.1 million in the prior quarter.
  • Over the last five years, Income from Non-Controlling Interests for TSNDF reached as high as $2.3 million in Q4 2023 and fell as low as $351000.0 in Q1 2022.
  • Historically, Income from Non-Controlling Interests has averaged $1.6 million across 5 years, with a median of $1.7 million in 2024.
  • Across the five-year window, Income from Non-Controlling Interests soared 522.79% in 2023 and plunged 40.93% in 2025, its largest moves.
  • Year by year, Income from Non-Controlling Interests stood at $1.0 million in 2022, then jumped by 124.66% to $2.3 million in 2023, then retreated by 27.42% to $1.7 million in 2024, then slumped by 34.05% to $1.1 million in 2025, then fell by 5.04% to $1.1 million in 2026.
  • Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were $1.1 million in Q1 2026, $1.1 million in Q4 2025, and $1.2 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Haleon 89.42 Bn 87.55 Bn - -
2 Teva Pharmaceutical Industries 35.91 Bn 32.16 Bn 1.97 Bn -
3 Zoetis 32.72 Bn 30.78 Bn 1.62 Bn -
4 Takeda Pharmaceutical 27.65 Bn 23.59 Bn 4.39 Bn 395,346.10
5 United Therapeutics 23.11 Bn 20.96 Bn 648.10 Mn -
6 RedHill Biopharma 21.80 Bn 21.80 Bn - -
7 Viatris 20.30 Bn 18.50 Bn 1.16 Bn -
8 Neurocrine Biosciences 17.88 Bn 16.56 Bn 800.70 Mn -12.70 Mn
9 Elanco Animal Health 12.65 Bn 12.22 Bn 785.00 Mn -
10 TerrAscend 161.95 Mn 161.48 Mn 34.60 Mn 1.06 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 1.06 Mn
Dec 31, 2025 1.11 Mn
Sep 30, 2025 1.21 Mn
Jun 30, 2025 1.28 Mn
Mar 31, 2025 1.30 Mn
Dec 31, 2024 1.69 Mn
Sep 30, 2024 1.73 Mn
Jun 30, 2024 1.94 Mn
Mar 31, 2024 2.20 Mn
Dec 31, 2023 2.32 Mn
Sep 30, 2023 2.16 Mn
Jun 30, 2023 2.14 Mn
Mar 31, 2023 2.19 Mn
Dec 31, 2022 1.03 Mn
Sep 30, 2022 2.23 Mn
Jun 30, 2022 945,000.00
Mar 31, 2022 351,000.00
Dec 31, 2021 556,000.00
Sep 30, 2021 1.41 Mn
Jun 30, 2021 998,000.00